Multidrug rezistant pulmonary tuberculosis research hub

A randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis (DRTB-HDT).

This study is testing two new medicines alongside regular treatment for a type of tough-to-treat lung infection called rifampicin-resistant tuberculosis. Researchers want to see if these new medicines improve recovery, reduce the infection, and are safe to use.